Drug Sponsors

T2 Biosystems completes $40M Series E financing for T2Candida clinical programs

Friday, March 29, 2013 12:26 PM

Lexington, Mass.-based T2 Biosystems has completed a $40 million financing to support the clinical programs and commercialization of T2Candida, the Company's flagship molecular diagnostic test panel for the sensitive and rapid identification of species-specific Candida fungal infections directly from whole blood.

More... »

Actavis to expand Florida manufacturing facility, create 220 jobs

Wednesday, March 27, 2013 10:55 AM

Actavis, a specialty pharmaceutical company formerly known as Watson Pharmaceuticals, plans to expand its pharmaceutical manufacturing and warehousing facilities in Davie, Fla., resulting in the creation of 220 jobs.

More... »

Ziopharm terminates development of palifosfamide in metastatic soft tissue sarcoma

Wednesday, March 27, 2013 09:57 AM

Ziopharm Oncology, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that its phase III trial of palifosfamide (ZIO-201) for the treatment of metastatic soft tissue sarcoma in the first-line setting (PICASSO 3) did not meet its primary endpoint of progression-free survival (PFS).

More... »

Shire to acquire SARcode Bioscience, expand presence in ophthalmology

Monday, March 25, 2013 09:42 AM

Global specialty biopharmaceutical company Shire has agreed to acquire SARcode Bioscience, a Brisbane, Calif.-based privately held biopharmaceutical company. The acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase III compound—Lifitegrast—currently under development for the signs and symptoms of dry eye disease, into Shire's portfolio.

More... »

AB-Biotics, GSK sign agreement to promote Neurofarmagen test in Brazil

Friday, March 22, 2013 04:01 PM

GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.

More... »

NeuroSearch to update its strategy, reduce staff

Wednesday, March 20, 2013 09:39 AM

NeuroSearch’s transfer of the Huntexil project to Teva Pharmaceutical Industries is now so advanced that the company foresees a significant reduction in the activity level in the near future. Therefore, NeruoSearch will take measures to adjust the organization to the lower activity level and at the same time update its company strategy.

More... »

Affymax cuts 75% of employees in midst of ongoing product investigation

Tuesday, March 19, 2013 03:34 PM

Palo Alto, Calif.-based Affymax will reduce its workforce as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving Omontys injection following the nationwide voluntary recall of the product from the market. Approximately 230 employees (or 75%) will be cut, including its commercial and medical affairs field organizations and other officers and employees.

More... »

AstraZeneca to establish strategic R&D centers, cut or relocate 4,100 workers

Monday, March 18, 2013 02:12 PM

Global biopharmaceutical company AstraZeneca announced plans to invest in strategic R&D centers in the U.K., the U.S. and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.

More... »

New Jersey to hire displaced pharmaceutical workers

Wednesday, March 13, 2013 02:08 PM

New Jersey has announced a financial hiring incentive to employers through the state Department of Labor and Workforce Development (LWD) if they hire and train former pharmaceutical industry employees. Employers willing to hire displaced pharmaceutical workers may reduce the cost to train new employees under this new on-the-job training program, which will reimburse each employer up to between 50% and 90% of a new hire’s salary for up to six months and a maximum of $14,000

More... »

Astellas, Ambit terminate collaboration on FLT3 kinase inhibitors

Wednesday, March 13, 2013 10:39 AM

Tokyo-based Astellas Pharma and San Diego-based Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013.

More... »